Enhanced Cancer Therapeutic Methods Utilizing OPCML Fragment

The present invention relates to improved cancer therapeutic methods utilizing OPCML fragments, enhancing tumor suppressor function, and providing personalized treatment options.

The original patent disclosed the use of OPCML fragments in cancer therapy, but had limitations in terms of efficacy and delivery. The present invention addresses these limitations by introducing novel combinations of OPCML fragments with other polypeptides, nanoparticles, and genotyping-based personalized treatment approaches.

The inventive concept encompasses four main aspects: enhancing the tumor suppressor function of OPCML through combination with other polypeptides, developing personalized treatment options based on cancer patient genotypes, improving delivery of OPCML fragments to tumor cells using nanoparticle carriers, and monitoring the efficacy of OPCML-based therapy through measurement of receptor tyrosine kinase inhibition. These improvements are achieved through the administration of polypeptides comprising OPCML fragments and second polypeptides that enhance binding to receptor tyrosine kinases, or through the use of nanoparticle carriers that facilitate targeted delivery.

The new claims introduce novel combinations of OPCML fragments with other polypeptides and nanoparticles, as well as genotyping-based personalized treatment approaches, which are not obvious from the original patent. The inventive concept's novelty lies in the synergistic effects achieved by these combinations, resulting in enhanced tumor suppressor function and improved treatment outcomes.

Alternative embodiments of the inventive concept include the use of different polypeptide combinations, nanoparticle carriers, and genotyping approaches. Variations may include the administration of OPCML fragments through different routes, such as oral or topical, or the use of different types of nanoparticles, such as liposomes or polymeric nanoparticles.

The inventive concept has significant commercial potential in the cancer therapy market, particularly in the areas of personalized medicine and targeted therapy. The market for cancer therapy is projected to grow significantly in the coming years, driven by the increasing incidence of cancer and the need for more effective treatment options.